Adaptive Immunotherapy for Nasopharyngeal Carcinoma

NCT07154069 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

802

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)

Interventions

RADIATION: Radical radiotherapy of nasopharynx and neck
DRUG: Capecitabine
DRUG: Concurrent chemoradiotherapy (cCRT)
DRUG: Toripalimab

Sponsor

Sun Yat-sen University